Trial intelligence / Profile preview

BGB-3111 in relapsed/refractory mantle cell lymphoma

CTR20160888Phase 2Completed

Sponsor
BeiGene
Start
Dec 2016
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Countries
1
01

Overview

A Phase 2 trial of zanubrutinib in mantle cell lymphoma (MCL), sponsored by BeiGene. Started Dec 2016; status: completed.

02

Drugs

zanubrutinib
03

Conditions

mantle cell lymphoma (MCL)

Beyond the preview

Go deeper on CTR20160888.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20160888.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call